Home » EU’s IMI, U.S. Critical Path Sign MoU on Medicine Development
EU’s IMI, U.S. Critical Path Sign MoU on Medicine Development
July 11, 2011
A new memorandum of understanding (MoU) between the U.S. Critical Path Institute (C-Path) and the EU’s Innovative Medicines Initiative (IMI) may help accelerate drug development by driving agreements on testing methods.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor